ArticleBMC gastroenterology2026
SULT1E1 suppresses hepatocellular carcinoma progression via activation of the TGF-β/SMAD signaling pathway and cell cycle arrest.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSulfotransferase family 1E member 1 (SULT1E1) is a key estrogen-metabolizing enzyme whose dysregulation has been implicated in several hormone-related malignancies. However, its expression pattern, biological function, and clinical significance in hepatocellular carcinoma (HCC) remain poorly understood.
methodsSULT1E1 expression was analyzed in HCC tissues and cell lines using public datasets (TCGA and GEO) and a retrospective cohort of 85 HCC patients. Gain-of-function experiments were performed to evaluate the effects of SULT1E1 on HCC cell proliferation, migration, stem-like properties, and cell cycle progression in vitro. Transcriptomic profiling, pathway enrichment analyses, and pharmacological inhibition were used to explore underlying mechanisms. Subcutaneous and orthotopic xenograft mouse models were employed to assess the in vivo effects of SULT1E1.
resultsSULT1E1 expression was significantly downregulated in HCC tissues and cell lines and was associated with poor prognosis. Overexpression of SULT1E1 suppressed HCC cell proliferation, migration, colony formation, and tumorsphere formation, while inducing G1 phase cell cycle arrest. Transcriptomic and enrichment analyses indicated that SULT1E1 is involved in the regulation of cell cycle–related pathways and activation of the TGF-β/SMAD signaling pathway. Mechanistically, SULT1E1 overexpression increased SMAD2/3 phosphorylation, and pharmacological inhibition of TGF-β signaling partially reversed its tumor-suppressive effects. In vivo, SULT1E1 overexpression significantly inhibited tumor growth in HCC xenograft models.
conclusionsSULT1E1 functions as a tumor suppressor in hepatocellular carcinoma by restraining cell proliferation, migration, and stem-like properties, at least in part through activation of the TGF-β/SMAD signaling pathway and induction of cell cycle arrest. These findings suggest that SULT1E1 may serve as a potential prognostic biomarker and therapeutic target in HCC.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.